NEW YORK – HuidaGene Therapeutics said Wednesday that it has licensed a CRISPR genome editing enzyme to Synthego.

纽约——HuidaGene Therapeutics周三表示，它已经向Synthego授权了一种CRISPR基因组编辑酶。

Under the terms of the deal, HuidaGene has granted Synthego manufacturing and commercialization rights for its high-fidelity Cas12 nuclease, known as hfCas12Max, as well as the right to sublicense the nuclease for therapeutic use.

根据协议条款，HuidaGene已授予Synthego高保真Cas12核酸酶（称为hfCas12Max）的制造和商业化权利，以及将核酸酶转授权用于治疗的权利。

Financial and other terms of the deal were not disclosed.

交易的财务和其他条款未披露。

'The combination of our advanced CRISPR GMP production capabilities and regulatory expertise with HuidaGene's next-generation nuclease technology is a crucial step toward advancing transformative cell and gene therapies,' Synthego CEO Craig Christianson said in a statement. 'The integration of hfCas12Max naturally aligns with our initiative to enhance the accessibility and efficiency of CRISPR tools.'.

Synthego首席执行官克雷格·克里斯蒂安森（CraigChristianson）在一份声明中说：“我们先进的CRISPR GMP生产能力和监管专业知识与HuidaGene的下一代核酸酶技术相结合，是推进转化性细胞和基因治疗的关键一步。”hfCas12Max的整合自然与我们提高CRISPR工具的可访问性和效率的倡议相一致。

In addition to editing performance, the hfCas12Max system fits into a single viral vector, an important requirement for many cell and gene therapies, the firms said.

这些公司表示，除了编辑性能外，hfCas12Max系统还可以整合到单一病毒载体中，这是许多细胞和基因疗法的重要要求。

Shanghai-based HuidaGene has developed novel CRISPR-Cas systems using its HG-Precise platform, including hfCas12Max.

总部位于上海的HuidaGene使用其HG Precise平台（包括hfCas12Max）开发了新型CRISPR-Cas系统。

In March, Synthego, based in Redwood City, California, spun off its engineered cell and CRISPR guide RNA business as EditCo Bio to focus on the therapeutic applications of CRISPR.

3月，总部位于加利福尼亚州红木市的Synthego将其工程细胞和CRISPR指导RNA业务剥离为EditCo Bio，专注于CRISPR的治疗应用。